News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
1 hr ago | Seeking Alpha
The Chinese issues have caused the stock price to fall and we believe this fall has created a buying opportunity.
6 hrs ago | Fox News
Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.
10 hrs ago | Pacific Business Times
Amgen became the first drugmaker to seek U.S. regulatory approval for a new class of cholesterol-lowering treatments after it submitted an application to the Food and Drug Administration on Thursday for evolocumab.
The HCV franchise has transformed Gilead in the past two years from a solid mid-tier biopharma company into a pharma giant with a market cap rivaling Merck and Pfizer.
MARTA, de la Ciudad de Atlanta, Selecciona a BRS Labs como Proveedor de Analtica de Video de Inteligencia Artificial para Mejorar la Seguridad Pblica )--Behavioral Recognition Systems, Inc. , creadora de AISight , la solucion analitica basada en inteligencia artificial que se autoensena a reconocer y alertar sobr... )--Fitch Ratings has affirmed ... (more)
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the U.S. Food and Drug Administration approved ELELYSO for injection for pediatric patients.
Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a $120bn megamerger, but what would such a deal bring to the Pharma Giant? In-Pharmatechnologist investigates.
Pfizer Inc. said Thursday that its candidate to vaccinate against a potentially fatal infection that harms patients' bowels has received fast-track designation from the U.S. Food and Drug Administration.
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. for Q2 2014.
On CNBC's Fast Money , Pete Najarian said that Pfizer is going higher. He thinks that it has a price target of $36.
The healthcare sector has been performing well over the last few months - in fact, most of the BioPharma companies have outperformed most of the sectors and the overall market itself.
Analysts at Deutsche Bank initiated coverage on Pfizer with a Buy rating. The target price for Pfizer is set to $34.
Our mission at Market News Video is to produce and distribute quality online videos about the stock markets and publicly traded companies.
On Tuesday, Burger King announced that it would spend some $11 billion to buy Tim Hortons Inc., a Canadian breakfast food chain, then merge Burger King into it, thereby turning what was once a major American company into a major Canadian one.
The firm set a price target of $34 for the drug manufacturer. Pfizer has a strong financial position, and an attractive valuation and dividend, according to Deutsche Bank analysts.
The Dow Jones Industrial Average spent the whole session above the 17,100 level, helped by a raft of strong economic data -- including a banner month for durable goods.
Updated: Fri Aug 29, 2014 01:24 pm
Copyright © 2014 Topix LLC